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ABSTRACT: The purpose of this study was to assess the
antimicrobial activity of a solid dispersion prepared by mixing
and grinding hinokitiol (HT) with α-cyclodextrin (αCD), β-
cyclodextrin (βCD), or γ-cyclodextrin (γCD). Antimicrobial
activity was evaluated by calculating the minimum inhibitory
concentration (MIC) and evaluating the change in the number of
bacteria over time. The test microbes used were two Gram-positive
bacteria (Bacillus subtilis and Staphylococcus aureus), two Gram-
negative bacteria (Escherichia coli and Pseudomonas aeruginosa), and
two fungi (Candida albicans and Aspergillus brasiliensis). Calcu-
lation of the MIC value of HT using the agar dilution method
revealed that the MIC of HT/CD inclusion complexes was lower
than that of HT alone. HT irreversibly inhibited the growth of microorganisms in a short amount of time. HT/CD complexes
retained the antimicrobial activity of HT as a result of including HT in a CD complex. These results suggest that inclusion of HT, an
antimicrobial component, using CDs could lead to appropriate control of the drug release rate and efficient display of antimicrobial
activity.
1. INTRODUCTION
Natural flavors are extracted from volatile compounds obtained
from plants.1 These compounds are generally used as flavoring
agents or fragrances in foods and cosmetics, and they act as
antibacterials, preservatives, or insecticides.2 Drug-resistant
bacteria have become more prevalent around the world, and
attention has focused again on fragrances that have long been
studied for their antibacterial activity. Many fragrances are
natural and also have a broad antibacterial spectrum.
Fragrances are reported to have antibacterial activity by
themselves as well as a high level of antibacterial activity when
used in combination with antibiotics.3 Thus, fragrances will
presumably be used as a new antimicrobial ingredient in
pharmaceuticals. However, fragrances are poorly soluble in
water, volatile, unstable, and highly reactive, so they often need
to be specially formulated.
Hinokitiol (HT) is a phenolic monoterpene (Figure 1A). It
is reported to have antibacterial, antifungal, antiviral, and anti-
inflammatory actions.4−8 HT is used in a wide range of fields,
such as pharmaceuticals, foods, and household goods; if it
readily exhibits a wide variety of activities, its use will expand
further in the future.9 However, HT has the sublimation
characteristics of a fragrance, and the fact that it is poorly
soluble in water is a concern. In addition, HT is susceptible to
external conditions such as photodecomposition, polymer-
ization, and condensation, limiting the utility of HT in terms of
its antimicrobial activity. Since these properties hinder the
development of products using HT, the water solubility of HT
and heat and light stability of HT need to be improved. In
recent years, studies on the formulation of antibacterial
substances using various additives have been reported.
Cyclodextrin encapsulation technology is a means to prevent
the development of resistant bacteria in that it enables the
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Figure 1. Chemical structures of (A) HT, (B) αCD, (C) βCD, and
(D) γCD.
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antimicrobial activity of guest molecules in a smaller amount
and suppresses the use of unnecessary antimicrobial sub-
stances. The current authors previously reported complex
formation using HT and cyclodextrin (CD).10,11 Formation of
a complex by HT and α, β, or γCD results in different
inclusion behaviors as well as different dissolution behaviors of
HT in water.
Cyclodextrin (CD) is a compound in which D-glucopyranose
is cyclically linked by α-1,4 bonds; CD is classified as α
cyclodextrin (αCD), β-cyclodextrin (βCD), or γ-cyclodextrin
(γCD) depending on whether it contains 6, 7, or 8
glucopyranoses. CDs have been used as host molecules to
form inclusion compounds (Figure 1B−D). CD is known to
have a hydrophilic rim at the entrance of the ring and outside
but a hydrophobic inner cavity; this allows it to incorporate
various hydrophobic guest molecules into its cavity to form
inclusion complexes.12 CDs are used in various fields since the
inclusion of guest molecules should improve solubility,13
stability,14 antibacterial action,15 and antioxidant action16 as a
result of the effects of physicochemical properties. The
formation of a complex between an antibiotic and CD is
expected to improve solubility, improve bioavailability by
improving drug permeability to the bacterial membrane
barrier, and change antibacterial activity and chemical stability.
CD enables efficient and stable supply of antibacterial activity
and is a useful material for the development of pharmaceuticals
and daily necessities. Several studies have improved the
antibacterial activity of fragrances by complexing them with
CDs.17,18 As an example, inclusion of guava leaf oil in
hydroxypropyl-β-cyclodextrin (HPβCD) improved the anti-
bacterial activity of HPβCD by improving its stability.19 The
current authors previously reported the effect of formation of
HT/γCD inclusion complexes on antibacterial activity.11
However, the detailed mechanism of the effect of inclusion
in CD on the antimicrobial activity of HT has not been
investigated. One of the purposes of this study is the evaluation
of Escherichia coli, a Gram-negative bacterium. E. coli is present
in the moist environment of community hospitals, as well as in
the human skin and intestinal tract. Therefore, exogenous
infections derived from the environment and endogenous
infections caused by indigenous bacteria of patients themselves
are regarded as factors causing hospital infections. It is
interesting that the HT/CD complex laid the foundation for
an antibacterial mechanism against E. coli. We hope to make
progress in research on Gram-positive bacterial species of HT/
CD complexes. To expand the use of HT, the current study
used HT as a natural antimicrobial component. This study
examined whether HT/CD inclusion complexes were formed
as a result of cogrinding. Moreover, this study examined the
effects of the formation of HT/CD inclusion complexes on the
antimicrobial activity of HT and its mechanism of action.
2. RESULTS AND DISCUSSION
2.1. Antibacterial Testing. An antimicrobial test using the
agar dilution method was performed with four microbes, and
MICs were calculated (Table 1) to assess the antimicrobial
activity of HT.
The MIC of HT alone was 80 μg/mL with respect to B.
subtilis, 160 μg/mL with respect to S. aureus, 80 μg/mL with
respect to E. coli, and 320 μg/mL with respect to P. aeruginosa.
Ground HT alone had an MIC similar to that of HT crystals.11
The PM of HT and αCD (molar ratio = 1:2), the PM of HT
and βCD (molar ratio = 1:1), and the PM of HT and γCD
(molar ratio = 1:1) had decreased MICs with respect to the
two Gram-positive bacteria and MICs like that of HT alone
with respect to the two Gram-negative bacteria. However, the
GM of HT and αCD (molar ratio = 1:2), the GM of HT and
βCD (molar ratio = 1:1), and the GM of HT and γCD (molar
ratio = 1:1) had MICs of 20 μg/mL with respect to B. subtilis,
40 μg/mL with respect to S. aureus, and 20 μg/mL with
respect to E. coli; antimicrobial activity increased about
fourfold compared to that of HT alone. In addition, the GM
of HT and αCD (molar ratio = 1:2), the GM of HT and βCD
(molar ratio = 1:1), and the GM of HT and γCD (molar ratio
= 1:1) had an MIC of 160 μg/mL P. aeruginosa; antimicrobial
activity increased about twofold compared to that of HT alone.
Essential oils are known to destroy the cell wall and
cytoplasmic membrane of Gram-positive bacteria; essential oils
cause microbes to leak their cytoplasmic contents and
subsequently inactivate those microbes.20 HT is a phenolic
compound with a hydroxyl group attached to a seven-member
ring, so it would presumably exhibit antimicrobial activity like
other phenolic compounds. Phenolic compounds are known to
damage the bacterial cell wall and inhibit biofilm formation by
bacteria.21 Previous studies revealed molecular interactions
between the hydroxyl group of HT and CD in a solid state.10,11
Molecular interactions between the hydroxyl group of HT and
CDs as a result of complex formation presumably contributed
to the reduced MICs with respect to different bacteria. As a
mechanism, it was hypothesized that HT efficiently reaches the
cell membrane by inclusion with CD, and it was decided to
evaluate the effect on the bacterial membrane.
2.2. Antifungal Testing. The antibacterial test indicated
that the antibacterial activity of HT with respect to bacteria
increased due to its inclusion in a CD. HT is known to act on
both bacteria as well as fungi.6 The MIC was calculated based
on antimicrobial testing using the agar dilution method (Table
2) to assess the activity of HT and HT/CD on fungi. Two test
fungi were chosen: C. albicans, which is a yeast (fungus) that
causes infections in humans, and A. brasiliensis, which is a
filamentous fungus.
The MIC of HT alone was 20 μg/mL with respect to C.
albicans and 20 μg/mL with respect to A. brasiliensis. Ground
HT alone had an MIC similar to that of HT alone. The MIC of
HT with respect to C. albicans has been reported previously,
and the MIC calculated in the current study was similar to that
reported previously. The PM of HT and αCD (molar ratio =
1:2), the PM of HT and βCD (molar ratio = 1:1), and the PM
Table 1. Antimicrobial Activity of HT/CD Systemsac
MIC (μg/mL)
samples B. sub S. a E. coli P. aer
CDs n.d. n.d. n.d. n.d.
HT intact 80 160 80 320
HT ground 40 40 80 320
PM (HT/αCD = 1:2) 40 80 80 320
PM (HT/βCD = 1:1) 40 80 80 320
PM (HT/γCD = 1:1)d 40 80 80 320
GM (HT/αCD = 1:2) 20 40 20 160
GM (HT/βCD = 1:1) 20 40 20 160
GM (HT/γCD = 1:1)d 20 40 20 160
aB. sub: Bacillus subtilis, E. coli: Escherichia coli, S. a: Staphylococcus
aureus, P. aer: Pseudomonas aeruginosa. bAll MIC values are converted
into HT concentration. cn.d.: not determined. dValues from Suzuki et
al., 2015.
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of HT and γCD (molar ratio = 1:1) had MICs of 20 μg/mL
with respect to C. albicans and 20 μg/mL with respect to A.
brasiliensis. In contrast, the GM of HT and αCD (molar ratio =
1:2), the GM of HT and βCD (molar ratio = 1:1), and the GM
of HT and γCD (molar ratio = 1:1) had MICs of 10 μg/mL
with respect to C. albicans and 10 μg/mL with respect to A.
brasiliensis. Results of the antifungal test indicated that GMs
had a lower MIC than that of HT alone, so the antifungal
activity of HT with respect to C. albicans and A. brasiliensis was
enhanced. Nevertheless, a decrease in the MIC like that seen in
antibacterial testing was not evident. Essential oil components
are reported to exhibit antifungal action by inhibiting the
growth of hyphae.22 Moreover, essential oil components are
known to cause the cell wall to lose rigidity and integrity and
the loss of cytoplasmic components, resulting in cell death.23
Accordingly, differences in HT’s mechanism of action with
respect to bacteria and fungi or differences in the effects of CD
due to structural differences in bacteria and fungi may have an
effect. Essential oil components are reported to exhibit
different types of activity on bacteria and fungi.24 This is
attributable to structural differences in their cell walls. Essential
oil components are known to exhibit antifungal action by
affecting the functioning of mitochondria since they inhibit the
action of mitochondrial dehydrogenases involved in fungal
ATP synthesis.25 In addition, essential oils are known to inhibit
ergosterol synthesis by fungi.26 Ergosterol serves to stabilize
the fungal cell membrane and is not found in bacteria.
Therefore, it is possible that the fluctuation of the HT MIC
value in the HT/CD complex is due to a mechanism different
from that of bacteria.
Differences in HT’s mechanism of action on bacteria and
fungi as mentioned above may help to sustain the activity of
HT when HT/CD complexes are formed. In the future,
detailed evaluation of antibacterial activity using fungi is
required.
2.3. Time-Kill Assay. A time-kill assay is used to assess a
substance’s typical bactericidal and bacteriostatic actions with
respect to a bacterium over time. Thus, a time-kill assay was
performed to assess the time-dependent antibacterial action of
HT and HT/CD inclusion complexes on E. coli, a Gram-
negative bacterium. In this study, E. coli was selected as the
target strain for the time-kill assay test. E. coli, a Gram-negative
bacterium, is one of the major species of bacteria present in the
environment. Therefore, E. coli inhabits the digestive tract from
normal times and causes intestinal infectious diseases. In
addition, E. coli is a cause of urinary tract infections and is an
important bacterium in clinical susceptibility testing.
Some viable bacterial cells were noted in the control group
not treated with HT immediately after the start of the assay (0
h). In contrast, HT alone (320 μg/mL) caused a marked
decrease in the viable bacterial count at 3 h in comparison to
the count in the control group, and the detection limit was
reached at 6 h (Figure 2). This presumably indicates that HT
at a high concentration exhibited bactericidal action against E.
coli. The MIC of HT alone with respect to E. coli was
calculated based on antibacterial testing using the agar dilution
method. When HT alone (80 μg/mL) was added, a decrease in
the viable bacterial count was noted at 3 h. The viable bacterial
count tended to gradually decrease over the next 24 h. HT is
reported to slow microbial growth in a concentration-
dependent manner.27 The current results correlated with the
results of previous studies. Thus, HT inhibited bacterial growth
in a concentration-dependent manner. The extent to which
each CD alone inhibited the growth of E. coli was examined,
and the results revealed that CD alone behaved much like the
control group (data not shown). Thus, CDs did not inhibit the
growth of E. coli at the concentrations used in this study.
Moreover, an increase in the viable bacterial count was not
noted, so CDs presumably did not affect the growth of E. coli.
Similar testing was performed with the GM of HT and αCD
(molar ratio = 1:2), the GM of HT and βCD (molar ratio =
1:1), and the GM of HT and γCD (molar ratio = 1:1). A GM
of HT and αCD (molar ratio = 1:2), a GM of HT and βCD
(molar ratio = 1:1), and a GM of HT and γCD (molar ratio =
1:1) with an HT concentration of 80 μg/mL caused the viable
bacterial count to gradually decrease at 24 h (Figure 3a). The
GM of HT and αCD (molar ratio = 1:2), the GM of HT and
βCD (molar ratio = 1:1), and the GM of HT and γCD (molar
ratio = 1:1) gradually inhibited the growth of E. coli compared
to HT alone. The GM of HT and γCD (molar ratio = 1:1) in
particular inhibited growth in a time-dependent manner. A PM
of HT and αCD (molar ratio = 1:2), a PM of HT and βCD
(molar ratio = 1:1), and a PM of HT and γCD (molar ratio =
1:1) containing the same concentration of HT behaved like
HT alone. In addition, substantial differences in the effects of
HT on E. coli were not noted, as a result of which CD was
used. In contrast, the GM of HT and αCD (molar ratio = 1:2),
the GM of HT and βCD (molar ratio = 1:1), and the GM of
HT and γCD (molar ratio = 1:1) with a high concentration of
HT (320 μg/mL) behaved like HT alone (Figure 3b). The
GM of HT and γCD (molar ratio = 1:1) in particular caused
the bacterial count to reach the detection limit at 3 h, so it
quickly inhibited growth compared to HT alone. In contrast,
the GM of HT and αCD (molar ratio = 1:2) and the GM of
Table 2. Antifungal Activity of HT/CD Systemsac
MIC (μg/mL)
samples C. alb A. bra
CDs n.d. n.d.
HT intact 20 20
HT ground 20 20
PM (HT/αCD = 1:2) 20 20
PM (HT/βCD = 1:1) 20 20
PM (HT/γCD = 1:1) 20 20
GM (HT/αCD = 1:2) 10 10
GM (HT/βCD = 1:1) 10 10
GM (HT/γCD = 1:1) 10 10
aC. alb: Candida albicans, A. bra: Aspergillus brasiliensis. bAll MIC
values are converted into HT concentration. cn.d.: not determined.
Figure 2. Time-kill curves for E. coli in the presence of intact HT.
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HT and βCD (molar ratio = 1:1) gradually inhibited growth at
3 h compared to HT alone. The GM of HT and βCD (molar
ratio = 1:1) caused the colony count to decrease over time for
up to 12 h, so the release of HT was presumably inhibited as a
result of inclusion in a CD.
HT/CD complexes inhibited the growth of E. coli in a short
amount of time compared to HT alone. A factor for this is
presumably the faster rate at which HT reached the surface of
bacterial cells as a result of its inclusion in a CD. In the current
study, PMs behaved like HT alone, so this phenomenon
should be specific to inclusion complex formation. According
to Kogawa et al., a drug from a CD complex is delivered to the
lipophilic bacterial membrane, causing the drug to exhibit its
pharmacological action.28 In the current study, HT/CD
complexes exhibited faster antibacterial action than HT
alone; one factor for this is presumably the fact that CD
transports HT to the surface of bacterial cells.29 In addition,
HT exhibited differing antibacterial actions in αCD, βCD, or
γCD complexes, so differences in a CD’s affinity for a bacterial
cell membrane presumably led to differences in the ability of
HT to reach the cell membrane.
2.4. Measurement of Membrane Potential. Changes in
the membrane potential of a bacterium as a result of the
addition of CDs were assessed to fully elucidate the
mechanism of antimicrobial action of HT/CD inclusion
complexes. The membrane potential plays an important role
in cytophysiological processes. Moreover, the membrane
potential reflects the integrity and energy state of the cell
membrane and the cell’s survival rate. Typically, loss of the
membrane potential is known to occur in conjunction with an
increase in membrane penetration. Thus, HT and CD were
tested using DiBAC4(3), a voltage-sensitive dye, to determine
whether they affected the membrane potential of a bacterium.
The test bacterium used was E. coli, which is a Gram-negative
bacterium. Testing was performed using flow cytometry
(FCM).30,31
The assay of the membrane potential revealed that
DiBAC4(3) had a fluorescence intensity in the range of 0−
101 in the untreated sample (negative control) (Figure 4).
Thus, the untreated sample had only viable bacterial cells, so
the fluorescence intensity of viable bacterial cells was close to
0, indicating a low level of fluorescence. In contrast,
DiBAC4(3) had a fluorescence intensity in the range of 10
1−
102 in the heated sample (control). Thus, the heated sample
had only dead bacterial cells, so the fluorescence intensity of
dead bacterial cells was close to 102, indicating a high level of
fluorescence. CCCP is an uncoupling agent that is used to
depolarize the cell membrane. The assay was performed with
CCCP as a positive control. Results were similar to those for
the heated sample. DiBAC4(3) is a slow-acting voltage-
sensitive probe. Typically, DiBAC4(3) enters depolarized
cells, where it binds with intracellular proteins or the cell
membrane, and then strongly fluoresces.32 An increase in
depolarization indicates further inflow of the anionic dye and
increased fluorescence. Thus, the dye weakly fluoresced in
polarized viable bacterial cells and strongly fluoresced in
depolarized dead bacterial cells.
Fluorescence increased with αCD, βCD, and γCD when
some bacterial cells were viable or dead. Thus, the addition of
CD may have disrupted the membrane potential of E. coli. In
contrast, HT alone did not cause marked changes in the
electric potential at a concentration of 20 μg/mL. In addition,
the membrane potential shifted at a concentration of 80 μg/
mL. These findings suggest that HT affected the membrane
potential of the bacterium in a dose-dependent manner.
However, only slight changes in the membrane potential were
noted, so presumably, a certain concentration of HT must be
present to cause the membrane potential to change. Therefore,
it was speculated that the HT/CD complex was caused by the
change in bacterial membrane potential caused by CD, and the
Figure 3. (a) Time-kill curves for E. coli in the presence of HT/CD
systems (HT concentration: 80 μg/mL). (b) Time-kill curves for E.
coli in the presence of HT/CD systems (HT concentration: 320 μg/
mL).
Figure 4. Flow cytometric analysis of E. coli with HT and CDs. (A)
Control, (B) negative control, (C) positive control (CCCP), (D)
αCD, (E) βCD, (F) γCD, (G) intact HT (20 μg/mL), and (H) intact
HT (80 μg/mL).
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effective antibacterial action of HT was expressed by increasing
the membrane permeability of HT.
2.5. Flow Cytometric Analysis of Bacterial Cells. The
LIVE/DEAD BacLight Bacterial Viability Kit was used to
assess the cell membrane damage caused by HT to determine
whether or not HT and CD affected the bacterial cell
membrane.33 BacLight simultaneously stains samples with two
nuclear staining reagents (SYTO9: green and PI: red) with
different degrees of cell membrane penetration; this allows
differentiation of viable cells (undamaged) and dead cells
(damaged). This property allows a determination of whether
bacterial cells are viable or dead based on whether they are
damaged or not, and whether HT has caused membrane
damage or not was determined based on those results. The test
bacterium used was E. coli, which is a Gram-negative
bacterium.
HT alone increased the fluorescence intensity of PI
(indicating the dead bacterial count) in a dose-dependent
manner (Figure 5). The viable bacterial count tended not to
increase again over time, so HT presumably had irreversible
antibacterial action, i.e., bactericidal action, on E. coli. Thus,
HT may exhibit antibacterial action by damaging the cell
membrane.
When CD alone was added, in contrast, the viable bacterial
count was roughly similar to that in the control at 3, 6, and 24
h. CD alone presumably did not damage the bacterial cell
membrane (a physical barrier) (Figure 6). This finding
indicates that CD alone does not affect the bacterial cell
membrane.
A number of viable bacterial cells were exposed to HT for 24
h when the GM of HT and αCD (molar ratio = 1:2) was
added (Figure 7). E. coli were lysed as a result of exposure to
HT, so cells did not fluoresce since they were not stained by
the nuclear staining reagents. Dead bacterial cells were not
noted, and viable bacterial cells may have increased in relative
terms. Adding the GM of HT and βCD (molar ratio = 1:1)
Figure 5. Flow cytometric analysis of E. coli with intact HT. (A) HT
40 μg/mL, (B) HT 80 μg/mL, (C) HT 160 μg/mL, and (D) HT 320
μg/mL.
Figure 6. Flow cytometric analysis of E. coli with CDs. (A) Control,
(B) αCD, (C) βCD, and (D) γCD.
Figure 7. Flow cytometric analysis of E. coli with GMs. (A) GM of
HT and αCD (molar ratio = 1:2) 40 μg/mL, (B) GM of HT and
βCD (molar ratio = 1:1) 40 μg/mL, and (C) GM of HT and γCD
(molar ratio = 1:1) 40 μg/mL.
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resulted in delayed bactericidal action of HT compared to that
of HT alone at every concentration. This may indicate that the
release of HT was inhibited as a result of its inclusion in βCD.
Adding the GM of HT and γCD (molar ratio = 1:1) resulted in
the death of about 61% of the bacterial cells at 3 h and the
death of about 75% of the bacterial cells 24 h later. These
findings presumably indicate that the GM of HT and γCD
(molar ratio = 1:1) exhibited antibacterial action by causing
the rapid release of HT.
These findings indicate that inclusion of HT in a CD is key
to HT/CD complexes reaching the cell membrane. This
inclusion enhances HT’s penetration of the bacterial cell
membrane (a barrier) and may increase the antimicrobial
activity of HT. HT at a low concentration behaved differently
than HT alone, so the antibacterial action of HT may be
efficiently displayed as a result of the formation of an inclusion
complex. Differences in the extent of HT’s antibacterial action
were evident in HT/CD complexes formed by different CDs.
This indicates that inclusion in a CD contributes to the
structural stability of HT. A previous assessment of the
physical properties of HT/CD complexes revealed different
forms of inclusion depending on the CD used. This causes
changes in the structural state of the HT molecule in a CD and
may be reflected in differences in HT’s potency against
different bacteria. The main Gram-negative bacteria that pose a
problem in medical infection control are E. coli and P.
aeruginosa. In particular, the HT/CD complex can improve the
antibacterial activity of E. coli as a Gram-negative bacterium
and elucidate the foundation of its antibacterial mechanism; it
will be a useful subject for research and development as a
future clinical application.
3. CONCLUSIONS
The current results revealed that HT and HT/CD complexes
are active against bacteria and fungi. HT irreversibly inhibited
the growth of microbes in a short amount of time. In each of
the antimicrobial tests, there was no decrease in antimicrobial
activity even if HT was included in a CD, and HT/CD
complexes exhibited activity equivalent to or greater than that
of HT alone. The mechanism of action may be due to the fact
that HT/CD complexation disturbed the cell membrane
potential of bacteria and improved the membrane permeability
of HT. Thus, including an antimicrobial component in CD
should lead to appropriate control of the rate of drug release
and efficient use of antimicrobial activity.
4. MATERIALS AND METHODS
4.1. Materials. 4.1.1. Chemicals. HT from FujiFilm Wako
Pure Chemical Corporation was used as it is. αCD, βCD, and
γCD were kindly provided by CycloChem and stored in a
humidity-controlled environment at a temperature of 40 °C
and an RH of 82%. Other reagents from FujiFilm Wako Pure
Chemical Corporation were of special reagent grade.
4.1.2. Preparation of Physical Mixtures and Ground
Mixtures. HT and αCD were weighed to obtain a molar
ratio of 1:2, and HT and βCD and HT and γCD were weighed
to obtain a molar ratio of 1:1. HT was mixed with αCD, βCD,
or γCD for 1 min using a Vortex Mixer to yield three physical
mixtures (PMs). Each PM (1 g) was placed on an aluminum
pan and then co-ground with a vibrating rod mill (TI-500ET,
CMT) for 60 min to serve as a ground mixture (GM).
4.2. Methods. 4.2.1. Antibacterial Testing. The minimum
inhibitory concentration (MIC) of HT as a result of agar
dilution was based on Standard M7-A5 of the Clinical and
Laboratory Standards Institute (CLSI) M7-A5; this determi-
nation was in accordance with the methods described by
Takeda et al.34,35 Four bacteria were tested: two Gram-positive
bacteria (Bacillus subtilis NBRC3134 and Staphylococcus aureus
JCM2413) and two Gram-negative bacteria (Escherichia coli
JCM5491 and Pseudomonas aeruginosa JCM6119). Mueller-
Hinton II Agar (MHA, BD) was used as the test medium. All
of the samples were added to 100 mL of MHA so that the
concentration of HT would be 320 μg/mL, and each mixture
was carefully stirred without producing bubbles. MHA
containing HT was serially diluted twofold with MHA to
prepare a medium with a twofold dilution of HT. The prepared
test medium was poured into a Petri dish, where it solidified. A
suspension of each test bacterium was prepared with 2.0 × 106
CFU/mL of each bacterium. Each test medium was inoculated
with 5 μL of that suspension and allowed to dry. Test plates
were cultured for 24 h in an incubator at 37 °C. Plates were
visually inspected for colony formation after culturing, and the
MICs of HT and HT/CD complexes with respect to each
species were determined.
4.2.2. Antifungal Testing. The antifungal action of HT was
assessed using the agar dilution method to calculate the MIC
of HT with respect to fungi. Two fungi were tested: Candida
albicans and Aspergillus brasiliensis. HT and HT/CD complexes
were prepared with sterile water and diluted with RPMI1640
medium (containing glutamine). Each solution was buffered to
a pH of 7.0 using 0.165 M 3-(N-morpholino)propanesulfonic
acid (MOPS) buffer. A sample was added so that the
concentration of HT would be 320 μg/mL, and the mixture
was carefully stirred without producing bubbles. RPMI1640
medium containing HT was serially diluted twofold with
RPMI1640 medium to prepare medium with a twofold
dilution of HT. A 3% agar solution was added to the prepared
test medium; the mixture was fully stirred and then poured
into a Petri dish, where it solidified. A suspension of each test
bacterium was prepared with 2.0 × 106 CFU/mL of each
bacterium. Each test plate was inoculated with 5 μL of that
suspension and allowed to dry. Test plates were cultured for
48−72 h in an incubator at 37 °C. Plates were visually
inspected for colony formation after culturing, and the MICs of
HT and HT/CD complexes with respect to each species were
determined.
4.2.3. Time-Kill Assay. A time-kill assay was performed
according to the methods of Baltch et al. based on CLSI
standards.36,37 Sterile PBS was sprayed on a test bacterium that
had been cultured on an agar slant to prepare a stock
suspension of the test bacterium. The stock suspension of the
test bacterium was added to Mueller-Hinton II Broth (MHB)
until the final concentration reached 1.0 × 108 CFU/mL.
Afterward, the suspension was shaken with a rotary shaker
(NR-3, TITEC) during culturing at 37 °C until its OD at 600
nm >0.1 according to an absorption spectrometer. The
suspension of the test bacterium was diluted with the test
solution (distilled water) until its final concentration reached
1.5 × 105 CFU/mL. A sample was added, and the suspension
was shaken (150 rpm) again at 25 °C. The culture solution was
collected immediately prior to adding a sample (0 h) and 3, 6,
12, and 24 h after a sample was added to serve as the stock
solution. The stock solution was applied to Trypticase Soy
Agar medium (TSA medium, BD), which was cultured at 37
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°C for 14−16 h. After culturing, colonies were counted, and
the concentration of E. coli (CFU/mL) in the stock solution
was calculated. All assays were performed in triplicate.
4.2.4. Measurement of Membrane Potential. A membrane
potential assay was performed using DiBAC4(3) (bis(1,3-
dibutylbarbituric acid)trimethine oxonol), and sodium salt
(Dojindo Laboratories) as an intracellular fluorescent probe.
The test bacterium used was a Gram-negative bacterium (E.
coli JCM5491). Carbonyl cyanide m-chlorophenylhydrazone
(CCCP) does not affect the electric potential of a cell
membrane, so it was used as a positive control. The cultured
bacterial solution was sterilized in an autoclave at 100 °C for
30 min to serve as the negative control. A bacterial solution
was prepared by shaking (130 rpm) a stock suspension of the
test bacterium during culturing at 37 °C for about 4 h until its
final concentration reached 5.0 × 106 CFU/mL. After the
bacterium and a sample were added to the test solution, the
mixture was shaken again (150 rpm) at 25 °C. The culture
solution was collected 1 h after a sample was added to serve as
the stock solution. The collected culture solution was
centrifuged. The supernatant was suctioned off and allowed
to react with the DiBAC4(3) reagent. Fluorescence intensity
was measured with the EPICS XL Flow Cytometer (Beckman
Coulter).
4.2.5. Flow Cytometric Analysis of Bacterial Cells (Assess-
ment of Membrane-Damaging Action). A membrane
damage assay was performed using the LIVE/DEAD BacLight
Bacterial Viability Kit (Molecular Probes, Inc.). The test
bacterium used was a Gram-negative bacterium (E. coli
JCM5491). A stock suspension of the test bacterium was
shaken (130 rpm) during culturing at 37 °C for about 4 h until
its final concentration reached 5.0 × 106 CFU/mL. After the
bacterium and a sample were added to the test solution, the
mixture was shaken again (150 rpm) at 25 °C. A sample was
added, and the culture solution was collected 6 and 24 h later
to serve as the stock solution. The collected culture solution
was centrifuged. The supernatant was suctioned off and
allowed to react with the BacLight reagent. After incubation at
37 °C for 15 min, live and dead bacterial cells were counted
with the EPICS XL Flow Cytometer (Beckman Coulter).
■ AUTHOR INFORMATION
Corresponding Author
Yutaka Inoue − Laboratory of Drug Safety Management,
Faculty of Pharmacy and Pharmaceutical Sciences, Josai
University, Sakado-shi, Saitama 3500295, Japan; orcid.org/
0000-0003-3419-343X; Phone: +81-49-271-7317;
Email: yinoue@josai.ac.jp; Fax: +81-49-271-7317
Authors
Rina Suzuki − Laboratory of Drug Safety Management, Faculty
of Pharmacy and Pharmaceutical Sciences, Josai University,
Sakado-shi, Saitama 3500295, Japan
Isamu Murata − Laboratory of Drug Safety Management,
Faculty of Pharmacy and Pharmaceutical Sciences, Josai
University, Sakado-shi, Saitama 3500295, Japan
Harue Nomura − Department of Microbiology, Faculty of
Pharmacy and Pharmaceutical Sciences, Josai University,
Sakado-shi, Saitama 3500295, Japan
Yasunori Isshiki − Department of Microbiology, Faculty of
Pharmacy and Pharmaceutical Sciences, Josai University,
Sakado-shi, Saitama 3500295, Japan
Ikuo Kanamoto − Laboratory of Drug Safety Management,
Faculty of Pharmacy and Pharmaceutical Sciences, Josai
University, Sakado-shi, Saitama 3500295, Japan
Complete contact information is available at:
https://pubs.acs.org/10.1021/acsomega.0c03222
Funding
This research was supported by Josai University.
Notes
The authors declare no competing financial interest.
■ REFERENCES
(1) Edris, A. E. Pharmaceutical and therapeutic potentials of
essential oils and their individual volatile constituents: A review.
Phytother. Res. 2007, 21, 308−323.
(2) Nazzaro, F.; Fratianni, F.; De Martino, L.; Coppola, R.; De Feo,
V. Effect of essential oils on pathogenic bacteria. Pharmaceuticals
2013, 6, 1451−1474.
(3) Gibbons, S.; Oluwatuyi, M.; Veitch, N. C.; Gray, A. I. Bacterial
resistance modifying agents from Lycopus europaeus. Phytochemistry
2003, 62, 83−87.
(4) Morita, Y.; Sakagami, Y.; Okabe, T.; Ohe, T.; Inamori, Y.; Ishida,
N. The mechanism of the bactericidal activity of hinokitiol. Biocontrol
Sci. 2007, 12, 101−110.
(5) Domon, H.; Hiyoshi, T.; Maekawa, T.; Yonezawa, D.; Tamura,
H.; Kawabata, S.; Yanagihara, K.; Kimura, O.; Kunitomo, E.; Terao, Y.
Antibacterial activity of hinokitiol against both antibiotic-resistant and
-susceptible pathogenic bacteria that predominate in the oral cavity
and upper airways. Microbiol. Immunol. 2019, 63, 213−222.
(6) Komaki, N.; Watanabe, T.; Ogasawara, A.; Sato, N.; Mikami, T.;
Matsumoto, T. Antifungal mechanism of hinokitiol against Candida
albicans. Biol. Pharm. Bull. 2008, 31, 735−737.
(7) Krenn, B. M.; Gaudernak, E.; Holzer, B.; Lanke, K.; Van
Kuppeveld, F. J.; Seipelt, J. Antiviral activity of the zinc ionophores
pyrithione and hinokitiol against picornavirus infections. J. Virol.
2009, 83, 58−64.
(8) Shih, M. F.; Chen, L. Y.; Tsai, P. J.; Cherng, J. Y. In vitro and in
vivo therapeutics of β-thujaplicin on LPS-induced inflammation in
macrophages and septic shock in mice. Int. J. Immunopathol.
Pharmacol. 2012, 25, 39−48.
(9) Choi, Y. G.; Bae, E. J.; Kim, D. S.; Park, S. H.; Kwon, S. B.; Na, J.
I.; Park, K. C. Differential regulation of melanosomal proteins after
hinokitiol treatment. J. Dermatol. Sci. 2006, 43, 181−188.
(10) Suzuki, R.; Inoue, Y.; Limmatvapirat, S.; Murata, I.; Kanamoto,
I. Molecular interactions of the inclusion complexes of hinokitiol and
various cyclodextrins. AAPS PharmSciTech 2017, 18, 2717−2726.
(11) Suzuki, R.; Inoue, Y.; Tsunoda, Y.; Murata, I.; Isshiki, Y.;
Kondo, S.; Kanamoto, I. Effect of γ-cyclodextrin derivative complex-
ation on the physicochemical properties and antimicrobial activity of
hinokitiol. J. Inclusion Phenom. Macrocyclic Chem. 2015, 83, 177−186.
(12) Ogawa, N.; Higashi, K.; Nagase, H.; Endo, T.; Moribe, K.;
Loftsson, T.; Yamamoto, K.; Ueda, H. Effects of cogrinding with β-
cyclodextrin on the solid state fentanyl. J. Pharm. Sci. 2010, 99, 5019−
5029.
(13) Brewster, M. E.; Loftsson, T. Cyclodextrins as pharmaceutical
solubilizers. Adv. Drug Delivery Rev. 2007, 59, 645−666.
(14) Ikuta, N.; Sugiyama, H.; Shimosegawa, H.; Nakane, R.; Ishida,
Y.; Uekaji, Y.; Nakata, D.; Pallauf, K.; Rimbach, G.; Terao, K.;
Matsugo, S. Analysis of the enhanced stability of R(+)-alpha lipoic
acid by the complex formation with cyclodextrins. Int. J. Mol. Sci.
2013, 14, 3639−3655.
(15) Reddy, D. N. K.; Kumar, R.; Wang, S. P.; Huang, F. Y.
Curcumin-C3 complexed with α-, β-cyclodextrin exhibits antibacterial
and antioxidant properties suitable for cancer treatments. Curr. Drug
Metab. 2019, 988−1001.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c03222
ACS Omega 2020, 5, 27180−27187
27186
(16) Inoue, Y.; Osada, M.; Murata, I.; Kobata, K.; Kanamoto, I.
Evaluation of solubility characteristics of a hybrid complex of
components of soy. ACS Omega 2019, 4, 8632−8640.
(17) Wang, J.; Zhang, H. H.; Liu, F.; Zhang, Y. P.; Zhao, Y. M.
Preparation, characterization and antimicrobial activity of inclusion
complexes of Myristica fragrans Hott. essential oil in β-cyclodextrins.
Pharmazie 2019, 74, 590−594.
(18) Ge, X.; Huang, Z.; Tian, S.; Huang, Y.; Zeng, C. Complexation
of carbendazim with hydroxypropyl-β-cyclodextrin to improve
solubility and fungicidal activity. Carbohydr. Polym. 2012, 89, 208−
212.
(19) Rakmai, J.; Cheirsilp, B.; Mejuto, J.; Simal-Gańdara, J.;
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